Cabaletta Bio Statistics
Share Statistics
Cabaletta Bio has 48.88M shares outstanding. The number of shares has increased by 14% in one year.
| Shares Outstanding | 48.88M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 1.19% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 41.37M |
| Failed to Deliver (FTD) Shares | 1.80K |
| FTD / Avg. Volume | 0.08% |
Short Selling Information
The latest short interest is 3.71M, so 7.58% of the outstanding shares have been sold short.
| Short Interest | 3.71M |
| Short % of Shares Out | 7.58% |
| Short % of Float | 8.96% |
| Short Ratio (days to cover) | 4.26 |
Valuation Ratios
The PE ratio is -13.73 and the forward PE ratio is -1.79.
| PE Ratio | -13.73 |
| Forward PE | -1.79 |
| PS Ratio | 0 |
| Forward PS | 21.9 |
| PB Ratio | 3.94 |
| P/FCF Ratio | -17.14 |
| PEG Ratio | n/a |
Enterprise Valuation
Cabaletta Bio Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 15.29, with a Debt / Equity ratio of 0.02.
| Current Ratio | 15.29 |
| Quick Ratio | 15.29 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 1.48 |
| Cash Flow / Debt | -15.04 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.29% and return on capital (ROIC) is -30.95%.
| Return on Equity (ROE) | -0.29% |
| Return on Assets (ROA) | -0.27% |
| Return on Capital (ROIC) | -30.95% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -497.61K |
| Employee Count | 136 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -86.37% in the last 52 weeks. The beta is 2.42, so Cabaletta Bio 's price volatility has been higher than the market average.
| Beta | 2.42 |
| 52-Week Price Change | -86.37% |
| 50-Day Moving Average | 3.69 |
| 200-Day Moving Average | 8.66 |
| Relative Strength Index (RSI) | 42.82 |
| Average Volume (20 Days) | 2.28M |
Income Statement
In the last 12 months, Cabaletta Bio had revenue of $0 and earned -$67.67M in profits. Earnings per share was $-1.65.
| Revenue | 0 |
| Gross Profit | -1.43M |
| Operating Income | -74.66M |
| Net Income | -67.67M |
| EBITDA | -73.23M |
| EBIT | - |
| Earnings Per Share (EPS) | -1.65 |
Balance Sheet
The company has $193.24M in cash and $5.02M in debt, giving a net cash position of $188.22M.
| Cash & Cash Equivalents | 193.24M |
| Total Debt | 5.02M |
| Net Cash | 188.22M |
| Retained Earnings | -233.24M |
| Total Assets | 204.41M |
| Working Capital | 162.63M |
Cash Flow
In the last 12 months, operating cash flow was -$53.55M and capital expenditures -$687.00K, giving a free cash flow of -$54.24M.
| Operating Cash Flow | -53.55M |
| Capital Expenditures | -687.00K |
| Free Cash Flow | -54.24M |
| FCF Per Share | -1.32 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
CABA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -58.93% |
| FCF Yield | -39.59% |
Analyst Forecast
The average price target for CABA is $27.5, which is 882.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $27.5 |
| Price Target Difference | 882.1% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Scores
| Altman Z-Score | -0.18 |
| Piotroski F-Score | 2 |